Selective serotonin reuptake inhibitors (SSRIs) were designed to treat depression by increasing serotonin levels throughout the brain via inhibition of clearance from the extracellular space. Although increases in serotonin levels are observed after acute SSRI exposure, 3-6 weeks of continuous use is required for relief from the symptoms of depression. Thus, it is now believed that plasticity in multiple brain systems that are downstream of serotonergic inputs contributes to the therapeutic efficacy of SSRIs. The onset of antidepressant effects also coincides with desensitization of somatodendritic serotonin autoreceptors in the dorsal raphe nucleus (DRN), suggesting that disrupting inhibitory feedback within the serotonin system may contribute to the therapeutic effects of SSRIs. Previously, we showed that chronic SSRI treatment caused a frequency-dependent facilitation of serotonin signaling that persisted in the absence of uptake inhibition. In this work, we use in vivo fast-scan cyclic voltammetry in mice to investigate a similar facilitation after a single treatment of the SSRI citalopram hydrobromide. Acute citalopram hydrobromide treatment resulted in frequencydependent increases of evoked serotonin release in the substantia nigra pars reticulata. These increases were independent of changes in uptake velocity, but required SERT expression. Using microinjections, we show that the frequency-dependent enhancement in release is because of SERT inhibition in the DRN, demonstrating that SSRIs can enhance serotonin release by inhibiting uptake in a location distal to the terminal release site. The novel finding that SERT inhibition can disrupt modulatory mechanisms at the level of the DRN to facilitate serotonin release will help future studies investigate serotonin's role in depression and motivated behavior. Selective serotonin reuptake inhibitors (SSRIs) increase extracellular serotonin levels by reducing serotonin transporter (SERT) function. These drugs were developed specifically to treat major depressive disorder, supported by evidence from the monoamine hypothesis linking abnormally low serotonin levels to symptoms of depression (Jacobsen et al. 2012). Although SSRIs increase extracellular serotonin levels after a single dose, 3-6 weeks elapse before they exert clinically meaningful antidepressant effects. Because of this time lapse, it is now believed that SSRI efficacy depends on plasticity in serotonergic function and its downstream targets (Blier and de Montigny 1998). This plasticity arises from two key effects of SSRI exposure: increases in extracellular serotonin levels, and reduced spontaneous firing of serotonergic neurons (Pineyro and Blier 1999). The former is a consequence of a functional shift in release and uptake equilibrium because of reductions in SERT function. The latter arises because of increased activation of 5-HT1A , homozygous SERT knockout; SNpr, substantia nigra pars reticulata; SSRI, selective serotonin reuptake inhibitor; t 1/2 , decay time from maximal release amplitu...